BioNexus Gene Lab Corp
BGLCUS売上高
$7M
百万USD
営業利益
$-3M
百万USD
純利益
$-3M
百万USD
ROE
-34.6%
最新FY
EPS
-
USD / 株
配当
-
USD / 株
業績推移
収益性
キャッシュフロー
財務状況
四半期業績
| 年度 | 期 | 売上高 | 純利益 | EPS |
|---|---|---|---|---|
| FY2021 | Q1 | $3M | $0M | - |
| FY2021 | Q2 | $3M | $0M | - |
| FY2021 | Q3 | $4M | $0M | - |
| FY2021 | FY | $13M | $1M | - |
| FY2022 | Q1 | $3M | $0M | - |
| FY2022 | Q2 | $2M | $-0M | - |
| FY2022 | Q3 | $3M | $-0M | - |
| FY2022 | FY | $11M | $-0M | - |
| FY2023 | Q1 | $2M | $-0M | - |
| FY2023 | Q2 | $3M | $-0M | - |
| FY2023 | Q3 | $3M | $-3M | - |
| FY2023 | FY | $10M | $-3M | - |
| FY2024 | Q1 | $2M | $-0M | - |
| FY2024 | Q2 | $2M | $0M | - |
| FY2024 | Q3 | $3M | $-1M | - |
| FY2024 | FY | $10M | $-2M | $-0.09 |
| FY2025 | Q1 | $2M | $-1M | $-0.04 |
| FY2025 | Q2 | $2M | $-1M | $-0.34 |
| FY2025 | Q3 | $3M | $-1M | $-0.40 |
| FY2025 | FY | $7M | $-3M | - |
| FY2026 | Q1 | $0M | $-1M | $-0.23 |
財務データ
| 指標 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| 売上高 | $0M | $11M | $13M | $11M | $10M | $10M | $7M |
| 営業利益 | $-0M | $1M | $1M | $-0M | $-3M | $-2M | $-3M |
| 純利益 | $-0M | $1M | $1M | $-0M | $-3M | $-2M | $-3M |
| 総資産 | $1M | $10M | $10M | $9M | $11M | $10M | $9M |
| 純資産 | - | - | - | - | - | - | - |
| 自己資本 | $1M | $7M | $7M | $7M | $10M | $8M | $9M |
| 営業CF | $-0M | $1M | $0M | $1M | $-1M | $-2M | $-2M |
| EPS | - | - | - | - | - | $-0.09 | - |
| BPS | $0.01 | $0.04 | $0.04 | $0.04 | $0.55 | $0.46 | $3.56 |
| ROE | -22.0% | 16.4% | 10.5% | -5.3% | -27.2% | -19.2% | -34.6% |